- €45.90m
- €42.10m
- €14.28m
- 60
- 23
- 55
- 40
Annual income statement for Biohit Oyj, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.12 | 9.36 | 11 | 13.1 | 14.3 |
| Cost of Revenue | |||||
| Gross Profit | 3.96 | 5.92 | 7.11 | 8.46 | 9.34 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 10.3 | 10.8 | 9.82 | 11.3 | 11.7 |
| Operating Profit | -3.17 | -1.48 | 1.13 | 1.82 | 2.56 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.26 | -1.3 | 0.868 | 2.19 | 2.87 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.31 | -1.5 | 0.601 | 1.85 | 2.57 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.31 | -1.5 | 0.601 | 1.85 | 2.57 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.31 | -1.5 | 0.601 | 1.85 | 2.57 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.22 | -0.1 | 0.04 | 0.122 | 0.169 |
| Dividends per Share |